Quick Answer
TriSalus Life Sciences, Inc. reported Cash and Equivalents of $20.44 million for fiscal year 2025.
TriSalus Life Sciences, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $20.44M | +139.8% |
| 2024 | $8.53M | -27.6% |
| 2023 | $11.78M | +25.1% |
| 2022 | $9.41M | +4586.3% |
| 2021 | $200.9K | -85.0% |
| 2020 | $1.33M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $22.69M | +101.0% | -14.4% |
| June 30, 2025 | $26.49M | +60.7% | +103.8% |
| March 31, 2025 | $13.00M | +227.5% | +52.5% |
| December 31, 2024 | $8.53M | -27.6% | -24.5% |
| September 30, 2024 | $11.29M | -47.2% | -31.5% |
| June 30, 2024 | $16.48M | +15750.9% | +315.1% |
| March 31, 2024 | $3.97M | +2802.1% | -66.3% |
| December 31, 2023 | $11.78M | +25.1% | -44.9% |
- TriSalus Life Sciences, Inc. showed an increase of +139.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2020–2025 period, TriSalus Life Sciences, Inc.’s cash and equivalents has grown by 1431.0% (from $1.33 million to $20.44 million).
- The most recent figure is from TriSalus Life Sciences, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: